6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A critical appraisal of IMPROVE-IT methodology, enrollment biases, statistical caveats, generalizability gaps, and conflict-of-interest considerations for ezetimibe plus simvastatin in post-ACS patients.
Long-term follow-up from the IMPROVE-IT trial reveals durable cardiovascular benefit of ezetimibe plus simvastatin, with no late safety signals and sustained MACE reduction beyond the original study period.
Deep-dive into IMPROVE-IT pre-specified and post-hoc subgroup analyses by age, sex, BMI, diabetes status, baseline LDL, and race. Which patients benefited most from ezetimibe added to simvastatin after acute coronary syndrome?
A deep-dive into the IMPROVE-IT trial (2015), which tested ezetimibe plus simvastatin versus simvastatin alone in 18,144 post-ACS patients and proved that lowering LDL cholesterol below traditional targets reduces cardiovascular events.
A deep-dive into the IMPROVE-IT trial's randomization, blinding, endpoint adjudication, statistical plan, and how each design choice shapes interpretation of ezetimibe-simvastatin results.
A deep-dive into the IMPROVE-IT trial (ezetimibe + simvastatin vs simvastatin alone post-ACS) and what its 6.4% relative MACE reduction means for prescribing, guidelines, and patients outside the trial population.